{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:28:10Z","timestamp":1791584890161,"version":"4.3.4"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Glioblastoma (GBM) remains one of the most lethal primary brain tumors despite maximal surgical resection, radiotherapy, and temozolomide. Immune checkpoint inhibitors have failed to demonstrate durable benefit in three large phase III trials (CheckMate 143, 498, and 548), underscoring profound, multilayered immune resistance. This narrative review synthesizes the immunosuppressive GBM microenvironment, situating the microglia\u2013myeloid-derived suppressor cell (MDSC)\u2013regulatory T cell (Treg) axis within the broader immune landscape, including dendritic cells, natural killer cells, exhausted CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells, neutrophils, and B cells. We distinguish ontogenetically distinct resident microglia from bone marrow\u2013derived macrophages, separate monocytic (M-MDSC) from polymorphonuclear (PMN-MDSC) subsets, and examine how radiotherapy reshapes immunity. We extend the immunometabolic discussion beyond indoleamine 2,3-dioxygenase (IDO) to the adenosine (CD39\/CD73\/A2A), arginine, hypoxia, lactate, and glutamine pathways, and critically analyze why checkpoint blockade has failed. We summarize emerging strategies, including CSF1R, CCR2, CXCR2, CD47\u2013SIRP\u03b1, STING, CD40, TGF-\u03b2, and IL-1\u03b2 targeting, together with candidate biomarkers such as circulating MDSCs, CSF1, IL-1\u03b2, multiplex immunofluorescence, spatial transcriptomics, and single-cell RNA sequencing, for rational patient selection. We frame these mechanisms as a single, self-reinforcing circuit integrating myeloid-driven immune regulation, metabolic reprogramming, and treatment-induced immune remodeling. We argue that future progress depends on biomarker-driven combinations that reprogram the myeloid compartment, relieve metabolic suppression, and actively inflame the tumor, integrated with radiotherapy and tailored to molecular context (IDH and MGMT status).\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1782775","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:43:30Z","timestamp":1786362210000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Reprogramming the immunosuppressive microenvironment in glioblastoma: the microglia\u2013MDSC\u2013Treg axis and translational therapeutic strategies"],"prefix":"10.3389","volume":"16","author":[{"given":"Hasan Ali","family":"Ayd\u0131n","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine, Zonguldak B\u00fclent Ecevit University","place":["Zonguldak, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emrah","family":"Keskin","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine, Zonguldak B\u00fclent Ecevit University","place":["Zonguldak, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Kalayc\u0131","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine, Zonguldak B\u00fclent Ecevit University","place":["Zonguldak, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013\u20132017","volume":"22","author":"Ostrom","year":"2020","journal-title":"Neuro Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","article-title":"Brain immunology and immunotherapy in brain tumours","volume":"20","author":"Sampson","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4185","article-title":"The role of microglia and macrophages in glioma maintenance and progression","volume":"19","author":"Hambardzumyan","year":"2016","journal-title":"Nat Neurosci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.009","article-title":"The microenvironmental landscape of brain tumors","volume":"31","author":"Quail","year":"2017","journal-title":"Cancer Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0047","article-title":"T-cell dysfunction in glioblastoma: applying a new framework","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.06.018","article-title":"Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas","volume":"137","author":"Franceschi","year":"2020","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2018.01.045","article-title":"The prognostic roles of gender and O6-methylguanine-DNA methyltransferase methylation status in glioblastoma patients: the female power","volume":"112","author":"Franceschi","year":"2018","journal-title":"World Neurosurg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26863","article-title":"Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma","volume":"10","author":"Poon","year":"2019","journal-title":"Oncotarget"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16223859","article-title":"Immunophenotypic profile of adult glioblastoma IDH-wildtype microenvironment: a cohort study","volume":"16","author":"Asioli","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.852950","article-title":"Glioblastoma microenvironment: from an inviolable defense to a therapeutic chance","volume":"12","author":"Di Nunno","year":"2022","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2006-008","article-title":"The role of human glioma-infiltrating microglia\/macrophages in mediating antitumor immune responses","volume":"8","author":"Hussain","year":"2006","journal-title":"Neuro Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.10.052","article-title":"Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies","volume":"17","author":"Bowman","year":"2016","journal-title":"Cell Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.85841","article-title":"Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype","volume":"1","author":"Gabrusiewicz","year":"2016","journal-title":"JCI Insight"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122264","article-title":"Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis","volume":"3","author":"Alban","year":"2018","journal-title":"JCI Insight"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nor042","article-title":"Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma","volume":"13","author":"Raychaudhuri","year":"2011","journal-title":"Neuro Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/NEN.0000000000000183","article-title":"Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue","volume":"74","author":"Gielen","year":"2015","journal-title":"J Neuropathol Exp Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1355","article-title":"Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner","volume":"10","author":"Bayik","year":"2020","journal-title":"Cancer Discov"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3773","article-title":"Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma","volume":"66","author":"Fecci","year":"2006","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0144","article-title":"CCL2 produced by glioma recruits regulatory T cells and myeloid-derived suppressor cells to the tumor microenvironment","volume":"76","author":"Chang","year":"2016","journal-title":"Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08997-x","article-title":"Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity","volume":"643","author":"Faust Akl","year":"2025","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1016\/j.cell.2024.03.029","article-title":"Integrative spatial analysis reveals a multi-layered organization of glioblastoma","volume":"187","author":"Greenwald","year":"2024","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov245","article-title":"Orally administered colony-stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study","volume":"18","author":"Butowski","year":"2016","journal-title":"Neuro Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad3018","article-title":"The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas","volume":"352","author":"Quail","year":"2016","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102400","article-title":"Targeting CSF1R alone or in combination with PD1 in experimental glioma","volume":"13","author":"Przystal","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/s41467-023-37328-9","article-title":"STING agonist-loaded, CD47\/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2130","article-title":"IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival","volume":"18","author":"Wainwright","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.22","article-title":"A phase 1 trial of oncolytic HSV-1 G207 to treat recurrent malignant glioma: safety, radiographic, and histopathological findings","volume":"22","author":"Markert","year":"2014","journal-title":"Mol Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0015","article-title":"Oncolytic viruses and their application to cancer immunotherapy","volume":"2","author":"Chiocca","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial (CheckMate 498)","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter (CheckMate 548)","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1391973","article-title":"Blocking the CD47-SIRP\u03b1 axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells","volume":"7","author":"Li","year":"2018","journal-title":"Oncoimmunology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02167-5","article-title":"The multilayered transcriptional architecture of glioblastoma ecosystems","volume":"57","author":"Nomura","year":"2025","journal-title":"Nat Genet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn6758","article-title":"Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma","volume":"15","author":"Ghosh","year":"2023","journal-title":"Sci Transl Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13014-023-02393-3","article-title":"Systematic review and pooled analysis of the impact of treatment-induced lymphopenia on survival of glioblastoma patients","volume":"19","author":"Saeed","year":"2024","journal-title":"Radiat Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1782775\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:43:30Z","timestamp":1786362210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1782775\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":43,"alternative-id":["10.3389\/fonc.2026.1782775"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1782775","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"1782775"}}